The COVID-19 pandemic made the world realize the importance of investing in healthcare infrastructure and developing ...

The path to discovering a blockbuster drug is often unpredictable. A promising molecule might be overlooked for decades, only ...

Lexicon Pharmaceuticals Inc (LXRX) stock saw a modest uptick, ending the day at $1.69 which represents a slight increase of $0.08 or 4.97% from the prior close of $1.61. The stock opened at $1.63 and ...

Starboard has approached two former Pfizer executives, Ian Read and Frank D’Amelio, to assist in its efforts, and they have ...

The State Health Plan's decision to end coverage of certain weight-loss prescription drugs has produced an unlikely and ...

Biomarin Pharmaceutical Inc (BMRN) stock saw a decline, ending the day at $68.16 which represents a decrease of $-1.50 or -2.15% from the prior close of $69.66. The stock opened at $69.58 and touched ...

The Federal Trade Commission staff is criticizing pharmaceutical benefit managers, which negotiate drug discounts. But ...

Report Ocean has published a new report on the Asia Pacific Contract Logistics Market, delivering an extensive analysis of key factors such as market restraints, drivers, and opportunities. The report ...

Arrowhead's plozasiran shows promising Phase 3 data for FCS, with potential blockbuster status, but faces competition. Learn ...

Johnson & Johnson is making the investment to help meet its 2030 target of launching 20 new medicines and expanding filings ...

Novartis reports strong Q2 2024 sales, with Kesimpta and Pluvicto showing significant growth. Learn more about NVSEF stock ...

As more and more analysts suggest space for further rate cuts, Vance Howard, CEO and Portfolio Manager at Howard Capital ...